KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cost of Revenue (2022 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Cost of Revenue for 4 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 11.58% year-over-year to $14.3 million, compared with a TTM value of $71.0 million through Dec 2025, up 56.84%, and an annual FY2025 reading of $71.0 million, up 56.84% over the prior year.
  • Cost of Revenue was $14.3 million for Q4 2025 at Recursion Pharmaceuticals, down from $14.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $21.8 million in Q1 2025 and bottomed at $7.8 million in Q1 2022.
  • Average Cost of Revenue over 4 years is $12.9 million, with a median of $12.3 million recorded in 2023.
  • The sharpest move saw Cost of Revenue plummeted 34.05% in 2023, then surged 119.17% in 2025.
  • Year by year, Cost of Revenue stood at $10.8 million in 2022, then dropped by 8.86% to $9.9 million in 2023, then grew by 29.49% to $12.8 million in 2024, then increased by 11.58% to $14.3 million in 2025.
  • Business Quant data shows Cost of Revenue for RXRX at $14.3 million in Q4 2025, $14.7 million in Q3 2025, and $20.2 million in Q2 2025.